Post-marketing study of cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison with Aspirin - Post-marketing study of cilostazol (Cilostazol Stroke Prevention Study II: CSPS II)

Otsuka Pharmaceutical Co., Ltd.0 个研究点目标入组 2,600 人开始时间: 2005年9月13日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1)Patients with hemorrhage or bleeding tendency (hemophilia, capillary fragility, intracranial hemorrhage, hemorrhage in the digestive tract, hemorrhage in the urinary tract, hemoptysis, and hemorrhage in the vitreous body) (2)Pregnant, possibly pregnant, or nursing women (3)Patients with ischemic heart failure (4)Patients with peptic ulcer (5)Patients with severer blood disorders (6)Patients with severe hepatic or renal (7)Patients with malignant neoplasm or patients who have received any therapy for malignant neoplasm within 5 years prior to entering the study (8)Patients with a history of hypersensitivity to salicylic acid formulations or ingredients of cilostazol tablets (9)Patients with aspirin asthma (asthma attacks induced by nonsteroidal antiinflammatory analgesic agents) or a history of aspirin asthma (10)Patients who are being treated with ticlopidine hydrochloride (11)Patients who are participating in another study for an investigational drug(12)Patients who are otherwise judged inappropriate for inclusion in the study by the investigators

发起方